Core Insights - The article highlights the significant performance of certain funds in the third quarter, particularly the "Yongying Technology Smart Selection" fund, which achieved a remarkable 194% increase, making it the top-performing fund of the year [1][2] - The report indicates a substantial growth in fund size, with "Yongying Technology Smart Selection" increasing from 1.166 billion to 11.521 billion yuan, nearly a ninefold increase in a single quarter [2] - The article also discusses the ongoing optimism in the innovative pharmaceutical sector, with funds like "Great Wall Pharmaceutical Industry Selection" showing over 100% growth [1][4] Fund Performance - "Yongying Technology Smart Selection" fund's top holdings include leading optical module stocks such as "Yizhongtian" (Xinyi Sheng, 300502), Zhongji Xuchuang (300308), and Tianfu Communication (300394), which significantly contributed to its net value [2] - The fund's share count surged from 700 million to 3.466 billion, resulting in a profit of 4.715 billion yuan for investors in the third quarter [2] - The "Great Wall Pharmaceutical Industry Selection" fund also saw its size grow from 1.132 billion to 1.790 billion yuan, with a share increase from 678 million to 932 million [5] Sector Insights - The global cloud computing industry remains a focal point, with AI model valuations increasing and a notable 100% quarter-on-quarter growth in token numbers [3] - The innovative pharmaceutical sector continues to attract attention, with funds maintaining high stock positions despite recent market adjustments [6][8] - The article suggests that the technology and pharmaceutical sectors may still have upward potential, although careful stock selection is advised [8] Future Outlook - The article indicates that the technology sector, particularly AI and cloud computing, is expected to see increased investment, with potential for new opportunities in the industry chain [9] - The innovative pharmaceutical sector is projected to strengthen its global competitiveness, supported by upcoming industry conferences and positive data trends [8] - The article emphasizes the importance of not solely relying on past performance to predict future outcomes in the cloud computing sector, highlighting the need for caution [9]

Core Insights - The article discusses a significant business development (BD) deal between Innovent Biologics and Takeda Pharmaceutical, marking a new milestone in the Chinese pharmaceutical industry with a total deal value of up to $11.4 billion [2][3]. Group 1: Partnership Details - Innovent Biologics announced a global strategic collaboration with Takeda to accelerate the development of its next-generation immuno-oncology (IO) and antibody-drug conjugate (ADC) therapies [2]. - The collaboration includes two late-stage therapies, IBI363 and IBI343, and an early-stage project, IBI3001, with Takeda paying an upfront fee of $1.2 billion, which includes a strategic equity investment of $100 million [2][3]. - The total potential milestone payments could reach approximately $10.2 billion, setting a record for BD transactions in the Chinese pharmaceutical sector [2]. Group 2: Co-Co Collaboration Model - The partnership adopts a "Co-Co" collaboration model, allowing both companies to share risks and benefits rather than simply licensing out rights for cash flow [3][4]. - Innovent and Takeda will co-develop IBI363 globally, sharing development costs and profits in a 40/60 ratio, with Takeda leading the development and commercialization efforts in the U.S. [4]. Group 3: Strategic Rationale - Innovent aims to build its global development and commercialization capabilities by leveraging this partnership, with plans to expand its U.S. team to support these efforts [4]. - The choice of Takeda as a partner is based on its deep experience in oncology and its alignment with Innovent's strategic goals [5]. Group 4: Product Pipeline - IBI363 is positioned for global development in non-small cell lung cancer (NSCLC) and colorectal cancer (CRC), with plans to initiate further clinical development for additional indications [5]. - IBI343 will focus on gastric and pancreatic cancers, leveraging Takeda's established presence and expertise in the Japanese market [5][6]. - IBI3001 is an early-stage ADC targeting B7-H3 and EGFR, with potential for broad application across various tumor types [6].

Major Events - Sinopharm (01801) has reached a global strategic cooperation with Takeda Pharmaceutical and plans to issue shares under general authorization [1] - China Unicom (00762) intends to spin off Zhinet Technology for listing on the Shenzhen Stock Exchange's ChiNext [1] - Laopuhuangjin (06181) plans to place approximately 3.7118 million new H-shares at a discount of about 4.50%, raising approximately HKD 2.707 billion [1] - Xinyi International (00732) intends to acquire approximately 11.43% equity in Xinyi Renshou through public bidding [1] - Xuan Bamboo Biotechnology-B (02575) will present clinical phase III research data for Pyrocilin as a first-line treatment for HR+/HER2- advanced breast cancer at ESMO 2025 [1] - Jinfang Pharmaceutical-B (02595) has completed the first patient dosing in the Ib/II phase study of KRAS G12D inhibitor GFH375 in combination with cetuximab or chemotherapy for advanced solid tumors [1] - Weihua Holdings (00622) plans to sell Shengjing H-shares for HKD 503 million [1] - Huajian Medical (01931) intends to change its English name to "ETHK Labs Inc." [1] - Nohui Health (06606) will have its listing status canceled starting October 27 [1] - Akun Real Estate (06900) will have its listing status canceled starting October 27 [1] - Jianzhong Construction (00589) will have its listing status canceled starting October 27 [1] Operating Performance - China Unicom (00762) reported a net profit attributable to shareholders of RMB 20 billion for the first three quarters, an increase of 5.1% year-on-year [2] - China Railway (00390) signed new contracts worth RMB 1,584.92 billion in the first nine months, a year-on-year increase of 3.7% [2] - China Communications Construction (01800) reported new contracts of RMB 1,339.97 billion for the first three quarters, a year-on-year growth of 4.65% [2] - Cathay Pacific (00293) saw a 21% year-on-year increase in passenger volume in September [2] - Tabo (06110) reported a profit attributable to equity holders of approximately RMB 789 million for the interim period, a decrease of 9.69% year-on-year [2] - Shanghai Petrochemical (00338) reported a net loss attributable to the parent company of RMB 432 million for the first three quarters [2]

Summary of the Conference Call for Innovent Biologics Company and Industry Overview - **Company**: Innovent Biologics - **Industry**: Biopharmaceuticals, specifically focusing on oncology therapies Key Points and Arguments 1. **Strategic Partnership with Takeda Pharmaceutical**: Innovent Biologics has entered into a strategic collaboration with Takeda Pharmaceutical, involving an upfront payment exceeding $1 billion, aimed at co-developing and commercializing innovative oncology therapies. This marks a significant step in Innovent's globalization strategy and enhances its global development and commercialization capabilities [2][3][8] 2. **Sales and Growth Targets**: Innovent aims to achieve sales of 20 billion RMB by 2027 and to become a leading global biopharmaceutical company by 2030, with a goal of having 15 globally registered clinical research products [2][4] 3. **Key Projects in Development**: The collaboration includes three main projects: - **363 (PD-1/L-2 molecule)**: Currently in registration studies in China and advancing international multi-center clinical trials - **3,343 (Claudin 18.2 ADC)**: Showing potential in pancreatic cancer treatment - **3,001 (ADC project)**: An option deal structure project [2][10][11] 4. **Financial Health**: Innovent has a robust financial position, with over $2 billion in cash and positive cash flow from its Chinese operations, enabling it to support its international expansion plans [4][20] 5. **Internationalization Efforts**: Innovent has established a research lab in the San Francisco Bay Area, which serves as its U.S. headquarters, and has a team of over 100 R&D personnel in the U.S. The company plans to expand this team further to support multiple products and international registration studies [6] 6. **Takeda's Advantages**: Takeda brings extensive pharmaceutical experience and resources, with projected revenues of $30 billion in 2024, and a strong R&D team of 4,500 personnel. This partnership is expected to accelerate Innovent's globalization process [2][7][19] 7. **Clinical Development Plans**: The development plans for the 363 and 343 products will continue as previously outlined, focusing on expanding their applications in various cancers, including colorectal and non-small cell lung cancer [16][18] 8. **Future Expectations**: Both companies are optimistic about the potential of the 363 and 343 projects, which are expected to revolutionize treatment options in their respective areas. The collaboration is seen as a foundation for deeper future cooperation [13][14] 9. **Budget and Investment Strategy**: Innovent plans to increase its investment in international clinical trials while balancing risk and return. The company will adopt a proof of concept (POC) approach before advancing to global Phase III trials, ensuring efficient investment returns [20] Other Important but Overlooked Content - **Regulatory Recognition**: The 363 molecule has received Breakthrough Therapy Designation (BTD) and Fast Track Designation (FTD) from regulatory authorities, indicating its potential significance in the market [12] - **Market Focus**: Innovent is particularly focused on expanding its presence in the U.S. market, which is a key component of its overall strategy [5][20] - **Collaboration Rationale**: The choice of Takeda as a partner was influenced by their strong commitment to the collaboration, alignment in clinical development plans, and their extensive experience in oncology [9][15]

Core Insights - The collaboration between Innovent Biologics and Takeda Pharmaceutical has reached a total transaction value of up to $11.4 billion, setting a record in the history of business development (BD) for Chinese innovative pharmaceutical companies [1][2][5]. Group 1: Collaboration Details - The strategic partnership aims to accelerate the global development and commercialization of Innovent's next-generation immuno-oncology (IO) and antibody-drug conjugate (ADC) therapies [1][2]. - The deal includes an upfront payment of $1.2 billion, which consists of a strategic equity investment of $100 million, and potential milestone payments of up to $10.2 billion [2][8]. - Innovent plans to allocate 80% of the funds for global pipeline research and development, with the remaining 20% for general corporate purposes [2]. Group 2: Financial Performance - Innovent reported a revenue of 5.953 billion yuan for the first half of 2025, representing a year-on-year increase of 50.6%, and a net profit of 834 million yuan, marking a turnaround from a loss of 393 million yuan in the same period last year [2]. - The gross margin improved by 3.1 percentage points to 86%, with R&D investment reaching 1 billion yuan, maintaining a leading position in the industry [2]. Group 3: Internationalization Efforts - Innovent is one of the first Chinese pharmaceutical companies to expand internationally, having previously licensed the exclusive rights of its drug, Sintilimab, to Eli Lilly for over $1 billion in 2020 [3]. - Despite setbacks in overseas markets, Innovent has continued to pursue international opportunities, including a recent exclusive licensing agreement with Roche for its drug IBI3009, which includes an upfront payment of $80 million and potential milestone payments of up to $1 billion [3]. Group 4: Product Pipeline and Market Potential - IBI363, a dual-specific antibody fusion protein, targets PD-1/IL-2α-bias and has a market potential exceeding $30 billion in first-line treatment for lung and colorectal cancers [6]. - IBI343 is the first ADC in the world to enter Phase III trials for both gastric and pancreatic cancers, with a combined market potential exceeding $20 billion [6]. - IBI3001 is a first-in-class ADC targeting B7-H3 and EGFR, currently in Phase I clinical trials, showcasing multiple anti-tumor mechanisms [7]. Group 5: Industry Trends - The recent BD transactions indicate a shift in the pharmaceutical industry towards next-generation technologies, with Innovent's collaboration focusing on "IO+ADC" strategies [5][8]. - The total transaction value for Chinese innovative drugs going overseas reached $102.996 billion in the first three quarters of 2025, with upfront payments exceeding $5.7 billion, indicating a significant increase in the global value chain position of Chinese innovative drug assets [9].

Core Insights - The collaboration between Innovent Biologics and Takeda Pharmaceutical has reached a total transaction value of up to $11.4 billion, setting a record in the business development (BD) history of Chinese innovative pharmaceutical companies [2][3][10] - The partnership aims to accelerate the global development and commercialization of Innovent's next-generation immuno-oncology (IO) and antibody-drug conjugate (ADC) therapies [2][3] Company Overview - Innovent Biologics, founded in 2011, focuses on the research, production, and sales of drugs for major diseases, with 16 products approved for market, including key products like Sintilimab [5] - Takeda Pharmaceutical, established in 1781, has evolved into a global pharmaceutical giant with revenues exceeding $30 billion, emphasizing its commitment to the Chinese market through its "Wu Ju Wei Lai" five-year strategic plan [6] Financial Details - The upfront payment for the collaboration is $1.2 billion, which includes $100 million from strategic equity investment, with potential milestone payments reaching up to $10.2 billion [3][9] - Innovent plans to allocate 80% of the funds for global pipeline research and 20% for general corporate purposes [3] Product Focus - The collaboration involves two late-stage therapies: IBI363 (PD-1/IL-2α-bias) and IBI343 (CLDN18.2 ADC), along with an option for IBI3001 (EGFR/B7H3 ADC) [2][6] - IBI363 is a globally pioneering dual-specific antibody that targets PD-1 and IL-2α, with a market potential exceeding $30 billion in lung and colorectal cancer [7] - IBI343 is the first ADC in clinical trials for both gastric and pancreatic cancers, with a combined market potential of over $20 billion [7][8] Strategic Implications - This BD transaction represents a significant strategic leap for Innovent, moving beyond traditional licensing models to a co-development and profit-sharing approach [9] - The deal reflects a broader trend in the Chinese pharmaceutical industry, transitioning from a reliance on domestic sales to a dual-driven international strategy [10]

Core Viewpoint - On October 22, the Hang Seng Index fell by 0.94% to close at 25,781.77 points, while southbound funds through the Stock Connect recorded a net purchase of HKD 10.018 billion [1] Group 1: Market Activity - The total trading volume for the Stock Connect on October 22 was HKD 106.582 billion, with a net purchase of HKD 10.018 billion [1] - The Shanghai Stock Connect accounted for HKD 66.693 billion in trading volume, with a net purchase of HKD 6.693 billion, while the Shenzhen Stock Connect had a trading volume of HKD 39.887 billion and a net purchase of HKD 3.325 billion [1] Group 2: Active Stocks - In the Shanghai Stock Connect, Alibaba-W had the highest trading volume at HKD 41.14 billion, followed by SMIC and Innovent Biologics with HKD 34.07 billion and HKD 32.39 billion respectively [1] - The top net purchase stock was the Tracker Fund of Hong Kong (盈富基金) with a net purchase of HKD 12.93 billion, despite a closing price drop of 1.05% [1] - Alibaba-W recorded the highest net sell amount at HKD 1.80 billion, closing down by 1.94% [1] Group 3: Shenzhen Stock Connect Activity - In the Shenzhen Stock Connect, Innovent Biologics led with a trading volume of HKD 26.84 billion, followed by Alibaba-W and Pop Mart with HKD 24.66 billion and HKD 23.36 billion respectively [2] - The Tracker Fund of Hong Kong (盈富基金) also had a net purchase of HKD 7.02 billion, closing down by 1.05% [2] - Innovent Biologics had the highest net sell amount at HKD 2.53 billion, with a closing price drop of 1.96% [2]

Summary of Innovent Biologics and Takeda Collaboration Call Company and Industry Overview - **Company**: Innovent Biologics (SEHK:01801) - **Industry**: Biopharmaceuticals, specifically focusing on oncology and immuno-oncology (IO) therapies Key Points and Arguments 1. **Strategic Partnership Announcement**: Innovent announced a significant global strategic collaboration with Takeda, focusing on the global development of next-generation oncology assets [3][10][8] 2. **Goals for Globalization**: Innovent aims to become a global premier biopharma by 2030, emphasizing the need for globally competitive products and a world-class organization [4][3] 3. **Product Pipeline**: Innovent has over 10 assets in various stages of development, with a goal of having at least five assets in pivotal MRCT phase three studies [5][4] 4. **Partnership History**: Innovent has a history of successful partnerships, including a long-standing collaboration with Lilly, which has expanded multiple times since 2015 [6][7] 5. **Collaboration Structure**: The partnership with Takeda includes co-development and co-commercialization of assets IBI363 and IBI343, with a 40:60 cost share and profit/loss share in the U.S. [9][17] 6. **Financial Aspects**: The deal is valued at over $1 billion in upfront payments, making it one of the largest strategic collaborations for a China-based biotech [10][11] 7. **Asset Details**: - **IBI363**: A PD-1/IL-2 bispecific therapy showing superior efficacy in non-small cell lung cancer and microsatellite stable colorectal cancer [16][17] - **IBI343**: A novel ADC targeting gastrointestinal cancers, with a focus on maximizing its global development potential [18][22] - **IBI301**: An EGFR/B7H3 ADC with potential for various tumor types [24] 8. **Market Positioning**: Takeda's strong global presence and expertise in oncology, particularly in the U.S. and Europe, are seen as key advantages for the partnership [12][13] 9. **Leadership and Expertise**: The partnership benefits from the leadership of experienced professionals from both companies, enhancing the potential for successful commercialization [14][15] 10. **Clinical Development Plans**: Innovent plans to initiate global phase trials for IBI363 in various indications, with a focus on generating high-quality clinical data [41][45] Additional Important Insights - **Long-term Value Creation**: The collaboration is expected to create long-term value not only through financial returns but also by enhancing Innovent's strategic capabilities [10][11] - **Regulatory and Market Access**: Innovent's strong financial position, with over $2 billion in cash, supports its pipeline development and global expansion efforts [45] - **Focus on Unmet Medical Needs**: Both companies emphasize addressing significant unmet medical needs in oncology, particularly in immune-resistant and cold tumors [39][60] - **Future Collaboration**: The partnership is positioned as a learning opportunity for Innovent to enhance its global capabilities through Takeda's extensive experience [13][31] This summary encapsulates the key points discussed during the call, highlighting the strategic importance of the partnership between Innovent Biologics and Takeda in advancing oncology treatments globally.

Core Viewpoint - The Hong Kong stock market experienced significant net inflows from northbound trading, with notable buying activity in specific stocks such as China National Offshore Oil Corporation (CNOOC), Semiconductor Manufacturing International Corporation (SMIC), and Pop Mart International. Conversely, stocks like Hua Hong Semiconductor, Xiaomi, and Alibaba faced net selling pressure [2][7]. Group 1: Northbound Trading Activity - Northbound trading recorded a net inflow of 100.18 billion HKD, with 66.93 billion HKD from the Shanghai Stock Connect and 33.25 billion HKD from the Shenzhen Stock Connect [2]. - The most bought stocks included the Tracker Fund of Hong Kong (02800), CNOOC (00883), and SMIC (00981) [2]. - The most sold stocks were Hua Hong Semiconductor (01347), Xiaomi Group-W (01810), and Alibaba Group-W (09988) [2]. Group 2: Stock Performance and Analysis - SMIC saw a net inflow of 18.49 billion HKD in buying, with a selling amount of 15.57 billion HKD, resulting in a total transaction volume of 34.07 billion HKD [3]. - CNOOC received a net buy of 14.24 billion HKD, supported by reports indicating a focus on increasing reserves and production amid external uncertainties [7]. - Pop Mart reported a strong third-quarter performance with revenue growth of 245% to 250% year-on-year, leading to an upgrade in earnings forecasts by Bank of America [8]. Group 3: Sector Insights - The semiconductor sector showed divergence, with SMIC gaining net inflows of 6.42 billion HKD while Hua Hong Semiconductor faced net outflows of 2.97 billion HKD [7]. - Analysts remain optimistic about the semiconductor industry's growth driven by artificial intelligence and domestic production capabilities amid U.S. export controls [7]. - The collaboration between Innovent Biologics and Takeda Pharmaceuticals is expected to yield significant financial benefits, with potential payments reaching up to 114 billion USD [8].

Innovent's Strategic Goals - Innovent aims to become a Global Premier Biopharma by 2027 and China's Top Biopharma by 2030[8] - The company plans to have ≥5 pipeline assets in global MRCT Phase 3 by 2030[8, 10] Takeda Collaboration - Innovent and Takeda have a strategic collaboration with a total deal size of up to $114 billion[20] - The collaboration includes $11 billion in cash upfront at a 20% premium and $100 million in equity investment[26] - Milestone payments could reach up to $102 billion[26] Takeda's Global Presence - Takeda has approximately 50000 employees and a presence in approximately 80 countries & regions[28] - Takeda's FY24 revenue was approximately $306 billion, with 44% from the U S, 29% from Europe & Canada, 12% from Japan, and 4% from China[28] Pipeline Development - IBI363 (PD-1/IL-2 α-bias) and IBI343 (CLDN182 ADC) are in global Phase 3 development[11, 40] - IBI3001 (EGFR/B7H3 ADC) is in global Phase 1 development[11, 40] IBI363 Clinical Data - IBI363 has shown promising ORR (Objective Response Rate) and mPFS (median Progression-Free Survival) in IO-resistant sqNSCLC, MSS colorectal cancer, and melanoma[50] - Over 1200 patients have been treated with IBI363 across multiple solid tumors[48] IBI343 Clinical Data - IBI343 has demonstrated clinical benefits in PDAC (Pancreatic Ductal Adenocarcinoma) and GC (Gastric Cancer), with lower GI toxicity AEs[62, 66] - In CLDN182+ GC, IBI343 showed significantly prolonged OS (Overall Survival) benefit compared to SoC (Standard of Care)[66]